Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
基本信息
- 批准号:8432820
- 负责人:
- 金额:$ 33.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2014-11-03
- 项目状态:已结题
- 来源:
- 关键词:AddressAdhesionsAffinityAgonistArterial Fatty StreakAtherosclerosisBindingBiological AssayBlocking AntibodiesBlood CirculationBlood ClotBlood PlateletsBlood coagulationCD36 geneCellsCholesterolCytoplasmic GranulesDataDevelopmentDiabetes MellitusDiseaseDyslipidemiasElementsFamilyFunctional disorderGenerationsHyperlipidemiaIn VitroInvestigationLecithinLigandsMediatingMetabolic syndromeMolecularMusOxidative StressPattern RecognitionPhasePhospholipase A2PhospholipidsPhysiologicalPlatelet ActivationPlayPropertyProteinsReceptor CellRecombinantsRegulationRiskRisk FactorsRoleRuptureSR-B proteinsSR-BI receptorSignal TransductionSiteSolidStagingTestingThrombosisToll-like receptorsUp-Regulationacute coronary syndromeadductin vivomacrophagenoveloverexpressionoxidized lipidreceptorreceptor functionresponsescavenger receptorsensor
项目摘要
A significant role for increased platelet reactivity in the pathophysiology of occlusive
arterial thrombosis is widely recognized. However, the mechanisms responsible for
enhancing platelet reactivity in vivo during hyperlipidemia are poorly understood. We
have recently isolated and structurally defined a novel family of oxidized choline
glycerophospholipids (oxPCCD36) that are present in vivo at sites of enhanced oxidative
stress. oxPCCD36 serve as high affinity ligands for scavenger receptors class B and
modulate platelet reactivity and thrombosis in oxidative stress. Our preliminary studies
demonstrated that a class of products formed as a result of degradation of oxPCCD36 by
PLA2 (carboxyalkylpyrolle protein adducts) is a new and powerful platelet agonist,
however, the receptors mediating its effect are not known. Platelets express a number of
receptors with pattern recognition properties, including several toll like receptors (TLRs).
A recent study suggested that platelet TLRs may modulate thrombosis when their
ligands are present in circulation. This proposal will address the hypothesis that platelet
TLRs alone, or in cooperation with scavenger receptors modulate platelet reactivity and
prothrombotic state induced by endogenous ligands generated in oxidative stress. This
proposal will also pursue the hypothesis that carboxyalkylpyrolle protein adducts serve
as novel ligands for platelet scavenger /toll like receptors and identify the mechanisms of
prothrombotic activity. Finally, we will continue the investigation of the molecular
mechanism of scavenger receptor BI regulation of platelet function and thrombosis in
dyslipidemia. Our preliminary data strongly support our hypothesis.
The Specific Aims are:
Aim1: To assess whether the platelet activating and prothrombotic activities of oxPCCD36
are mediated by platelet TLRs alone, or in cooperation with scavenger receptors class B.
Aim2: To investigate the role of scavenger receptor-BI in platelet function in
dyslipidemia and oxidative stress.
Aim3: To elucidate the mechanism and assess the physiological and pathophysiological
consequences of the interaction between carboxyalkylpyrolle protein adducts (CAPs)
and platelets.
血小板反应性增加在闭塞性脉管炎病理生理学中的重要作用
动脉血栓形成被广泛认识。然而,负责的机制
在高脂血症过程中增强体内血小板反应性的方法知之甚少。我们
最近分离并在结构上定义了一个新的氧化胆碱家族
甘油磷脂(oxPCCD 36),其存在于体内的增强的氧化的位点,
应力oxPC CD 36作为清道夫受体B类的高亲和力配体,
调节氧化应激中的血小板反应性和血栓形成。我们的初步研究
证明了由于oxPCCD 36的降解而形成的一类产物,
PLA 2(carboxyalkylpyrolle protein adducts)是一种新型的血小板激动剂,
然而,介导其作用的受体尚不清楚。坦率地说,
具有模式识别特性的受体,包括几种Toll样受体(TLR)。
最近的一项研究表明,血小板TLR可能调节血栓形成时,他们的
配体存在于循环中。该提案将解决血小板
TLR单独或与清道夫受体协同调节血小板反应性,
氧化应激产生的内源性配体诱导的血栓前状态。这
该提案还将继续研究羧烷基吡咯蛋白加合物的假设,
作为血小板清除剂/Toll样受体的新型配体,并确定
促血栓形成活性最后,我们将继续研究
清道夫受体BI调节血小板功能和血栓形成的机制
血脂异常我们的初步数据有力地支持了我们的假设。
具体目标是:
目的1:探讨oxPCCD 36对血小板活化和血栓形成的影响
由血小板TLR单独或与清道夫受体B类共同介导。
目的2:探讨清道夫受体-BI在血小板功能中的作用。
血脂异常和氧化应激。
目的3:阐明其机制,并评估其生理和病理生理学变化
羧烷基吡咯蛋白加合物(CAPs)之间相互作用的结果
和血小板。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
EUGENE A PODREZ其他文献
EUGENE A PODREZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('EUGENE A PODREZ', 18)}}的其他基金
Mechanism of atheroprotective function of Akt3 kinase
Akt3激酶的动脉粥样硬化保护功能机制
- 批准号:
8858363 - 财政年份:2015
- 资助金额:
$ 33.29万 - 项目类别:
Mechanism of atheroprotective function of Akt3 kinase
Akt3激酶的动脉粥样硬化保护功能机制
- 批准号:
9031810 - 财政年份:2015
- 资助金额:
$ 33.29万 - 项目类别:
Mechanism of atheroprotective function of Akt3 kinase
Akt3激酶的动脉粥样硬化保护功能机制
- 批准号:
9414577 - 财政年份:2015
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
7840709 - 财政年份:2009
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
7195835 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
8962155 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
9171370 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
7367193 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
6925309 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
Pathophysiological Activities of Oxidized Phospholipids
氧化磷脂的病理生理活性
- 批准号:
7031657 - 财政年份:2005
- 资助金额:
$ 33.29万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 33.29万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 33.29万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 33.29万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 33.29万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 33.29万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 33.29万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 33.29万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 33.29万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 33.29万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 33.29万 - 项目类别: